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Objective: Endoleaks are one of the unique complications seen after endovascular repair of thoracic aortic aneurysms
(TEVAR). This investigation was performed to evaluate the incidence and determinants of endoleaks, as well as the
outcomes of secondary interventions in patients with endoleaks, after TEVAR.
Methods:Over a 6-year period, 105 patients underwent TEVAR in the context of pivotal Food and Drug Administration
trials with the Medtronic Talent (n  64) and Gore TAG (n  41) devices. The medical and radiology records of these
patients were reviewed for this retrospective study. Of these, 69 patients (30 women and 39 men) had follow-up longer
than 1 month and were used for this analysis. The patients were evaluated for the presence of an endoleak, endoleak type,
aneurysm expansion, and endoleak intervention.
Results: The mean follow-up in this patient cohort was 17.3  14.7 months (range, 3-71 months). Endoleaks were
detected in 29% (20/69) of patients, of which 40% (8/20) were type I, 35% (7/20) were type II, 20% (4/20) were type
III, and 5% (1/20) had more than one type of endoleak. Patients without endoleaks experienced greater aneurysm sac
regression than those with endoleaks (2.89 9.1mm vs0.13 7.2mm), although this difference was not statistically
significant (P  .232). All but 2 endoleaks (90%; 18/20) were detected on the initial postoperative computed
tomographic scan at 30 days. Two endoleaks (10%; 2/20) developed late. The endoleak group had more extensive
aneurysms with significantly larger aneurysms at the time of intervention (69.4  10.5 mm vs 60.6  11.0 mm; P 
.003). Factors predictive of endoleak included male sex (P  .016), larger aneurysm size (P  .003), the length of aorta
treated by stent grafts (P  .0004), and an increasing number of stents used (P < .0001). No open conversions were
performed for treatment of endoleaks. Four (50%) of the eight type I endoleaks were successfully repaired by using
endovascular techniques. None of the type II endoleaks was treated by secondary intervention. During follow-up, the
maximum aneurysm diameter in the type II endoleak patients increased a mean of 2.94 7.2 mm (range, 4.4 to 17 mm).
Spontaneous thrombosis has occurred in 29% (2/7) of the type II endoleaks. Patients with type III endoleaks experienced
a decrease in mean maximal aneurysm diameter of 0.78  3.1 mm during follow-up.
Conclusions: Endoleaks are not uncommon after TEVAR. Many type I endoleaks may be treated successfully by
endovascular means. Short-term follow-up suggests that observational management of type II endoleaks is associated
with continued sac expansion, and these patients should be monitored closely. ( J Vasc Surg 2006;44:447-52.)As endovascular repair of abdominal aortic aneurysms
(EVAR) has become an accepted alternative to open ab-
dominal aortic aneurysm (AAA) repair, endovascular tech-
niques are now being used to treat thoracic aortic aneu-
rysms (TAAs).1-9 This endovascular approach (TEVAR)
offers a subset of TAA patients a less invasive technique to
exclude their aneurysms.3-9 It has also altered the way
patients are followed up after TAA repair. Unlike the min-
imal imaging required after open surgical repair, patients
undergoing endovascular repair of TAAs require lifelong
postoperative surveillance imaging.3-10 Although the imag-
ing modality and interval after aneurysm repair are topics
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doi:10.1016/j.jvs.2006.05.041that are being debated, some form of surveillance imaging
is needed to detect some of the unique complications of
TEVAR. These include stent graft migration and endoleak
formation.10-12
Although the detection and management of endoleaks
after EVAR have been well described, less is known about
endoleaks after TEVAR.10-14 This investigation was per-
formed to evaluate the incidence and determinants of en-
doleaks and the outcomes of secondary interventions in
patients with endoleaks after endovascular repair of TAAs.
METHODS
Approval by the institutional review board was granted
for this retrospective study. A review of consecutive clinical
cases and follow-up imaging studies was performed on
patients who underwent TEVAR. These procedures were
performed in the context of Food andDrug Administration
trials with the Medtronic Talent (Medtronic, Minneapolis,
Minn) and the Gore TAG (Gore, Flagstaff, Ariz) devices.
Review of the medical and radiology records of TAA
patients who underwent TEVAR between April 1999 and
May 2006 yielded a study group of 105 patients. Of these,
69 patients (30 women and 39 men) had follow-up longer
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for exclusion in the 36 patients with follow-up less than a
month were death (14), loss to follow-up (10), and imag-
ing that was not available for review (12). Of the deaths,
one was procedure related, four were cardiac related, four
were pulmonary, and one was caused by stroke; four causes
were unknown. The mean age was 72.9  9.2 years. The
Talent device was used in 41 (59%) patients, and the Gore
TAG device was used in 28 (41%) patients. After aneurysm
repair, imaging by triple-phase computed tomographic an-
giography (CTA) was performed at 1, 6, and 12 months
after stent graft implantation and annually thereafter for the
life of the patient. More frequent examinations were per-
formed when clinically indicated.
CTAwas performed with multidetector scanners (Gen-
eral Electric HISPEED CTi or LightSpeed Qxi; GE Med-
ical Systems, Milwaukee, Wis). The three-phase CTA con-
sisted of a noncontrast scan through the chest and upper
abdomen, followed by a chest and abdomen CTA using
120 mL of nonionic contrast. A 2-minute delayed com-
puted tomographic (CT) scan was then performed again
through the chest and upper abdomen.
The patients were evaluated for the presence of an
endoleak, endoleak type, aneurysm expansion, and en-
doleak intervention. The CTA examinations were evalu-
ated on GE workstations with multiplanar reformatting
capabilities to classify the endoleak type. Type I endoleaks
were classified on CTA on the basis of the location of the
endoleak in contiguity with the proximal or distal attach-
ment site, as well as early filling of the endoleak sac on the
CTA (Fig 1, A). Endoleaks were classified as type II en-
doleaks if the endoleak sac could not be seen communicat-
ing with the distal or proximal attachment site or if there
was delayed enhancement of the endoleak sac (Fig 1, B). If
an endoleak was associated with junctional separation of
two stent graft sections, it was called a type III endoleak
(Figure 1, C and D). For comparison of changes in aortic
sac diameter, all CTAs were further evaluated by a core
facility (Medical Metrx Solutions, Inc,West Lebanon, NH)
to allow for standardized measurements of maximal aortic
sac diameter.
Data are expressed as mean and standard deviation.
Comparison of continuous variables was made by using the
Student t test for independent variables. Categorical vari-
ables were compared by using the Fisher exact test. Differ-
ences were considered significant if the two-tailed P value
was .05.
RESULTS
The mean follow-up time for the patient cohort was
17.3  14.7 months (range, 3-71 months). Endoleaks
were detected in 29% (20/69) of patients. Forty percent
(8/20) were type I endoleaks, 35% (7/20) were type II,
20% (4/20) were type III, and 5% (1/20) had more than
one type of endoleak. All but two endoleaks (90%; 18/20)
were detected on the initial postoperative CT scan at
30 days. Two endoleaks (10%; 2/20) were detected late.
One type II endoleak was detected during the 6-monthfollow-up CT, whereas a type III endoleak was detected at
2 years in a patient who previously was without an en-
doleak.
When patients who developed endoleaks were com-
pared with those who did not, there was a similar age
distribution and prevalence of common medical comorbid
conditions (Table I). There were, however, significantly
more male patients in the endoleak group (80% vs 47%; P
.016). Follow-up in patients with endoleaks was longer
(21.6  15.3 months) when compared with that in those
without endoleaks (15.6  14.2 months), although this
failed to reach statistical significance (P  .125; Table I).
The endoleak group hadmore extensive aneurysms and
had significantly larger aneurysms at the time of interven-
tion (69.4  10.5 mm vs 60.6  11.0 mm; P  .003;
Table II). The section of aorta treated by stent grafts was
also significantly longer in endoleak patients (254.3 61.0
mm vs 192.9  58.8 mm; P  .0004). In addition, the
number of stents used was significantly higher for endoleak
patients when compared with those who did not develop
endoleaks (3.7  1.3 vs 2.2  1.0; P  .0001).
Aneurysm morphology, saccular or fusiform, was not
significantly different; 20% of endoleak patients and 35% of
patients without endoleaks had saccular morphology (P 
.265). Although more patients in the endoleak group re-
ceived the Talent device (75% vs 53%) compared with the
TAG device, this too failed to reach statistical significance
(P  .111; Table II).
During follow-up, the maximum aneurysm diameter in
all endoleak patients decreased an average of 0.13  7.2
mm (range,13 to17mm), compared with a decrease of
2.89 9.1 mm (range,44.7 to9.9 mm) for those with
no endoleak (P  .141; Table II). For all patients, the mean
changes in maximal aortic diameter were calculated by
comparing the baseline aortic diameter with the maximal
diameter at last follow-up, irrespective of endoleak treat-
ment. For patients with type I endoleaks, despite initial
increases (Fig 1, A), after endoleak treatment, the mean
maximum aneurysm diameter of all patients decreased an
average of 2.9  7.7 mm (Table III). This ranged from an
increase in diameter of 6.4 mm to a decrease in diameter of
13 mm. Patients with type II endoleaks had an increase in
their aneurysm size by a mean of 2.6  7.3 mm (range,
4.4 to 17 mm). Patients with type III endoleaks had a
mean decrease in aneurysm size of 0.78  3.1 mm (range,
3.3 to  3.3 mm). The change in aneurysm maximal
diameter was not statistically different when patients with
no endoleak were compared with those with type I (P 
.998), type II (P .136), or type III (P .649) endoleaks
(Table III). Furthermore, the difference in the change in
aneurysm diameter between patients with type I and type II
endoleaks was also not statistically significant (P  .209).
The difference between patients with type I and type III
(P  .648) endoleaks and the difference between those
with type II and type III (P .413) endoleaks was also not
statistically significant (Table III).
No open conversions where performed for the treat-
ment of endoleaks. Endovascular techniques were success-
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endoleaks. In the one patient with type I, II, and III
endoleaks, endovascular techniques were used to success-
fully treat the type III endoleak. Details of these remedial
procedures are shown in Table IV. In 12% (1/8) of
patients, endovascular techniques were unsuccessful in
treating the type I endoleak. This patient had successful
treatment of a proximal leak but has had persistence of the
distal leak and continues to be observed because he refused
further intervention. Spontaneous resolution of type I en-
doleaks occurred in three (38%) patients with small distal
Fig 1. Radiographic appearance of endoleaks. A, Three
endoleak. B, A type II endoleak is demonstrated on co
aneurysm sac and in communication with an intercosta
components (arrow) is demonstrated on computed tom
of the type III endoleak depicted inC. The aneurysm sac
image.endoleaks.Despite initial increases in sac diameter in patients with
type I endoleaks, those who underwent successful treat-
ment went on to have progressive decreases in sac diameter
after treatment (Fig 2, A). The one patient who had reso-
lution of the proximal leak with a persistent distal leak
initially experienced a decrease in sac diameter but had an
increase at last follow-up (Fig 2, A). Of the three patients
who had spontaneous resolution of the type I endoleak,
one had continued decreases, one had stabilization of the
sac, and one continued to have sac expansion (Fig 2, A).
All of the patients with type II endoleaks continue to
nsional reconstruction demonstrating a proximal type I
ted tomographic angiography with contrast filling the
ry (arrow). C, A type III endoleak between endograft
hic angiography. D, Three-dimensional reconstruction
ontained thrombus are not included in the reconstructed-dime
mpu
l arte
ograp
and cbe observed, and no secondary interventions have been
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has occurred in 29% (2/7) of patients with type II
endoleaks according to follow-up CTA. Despite throm-
bosis, however, sac regression has not occurred in these
patients (Fig 2, B ). None of the type III endoleaks
resolved spontaneously. As discussed, one patient with
complex endoleaks was treated and experienced resolu-
tion of the type III leak but had continued type I and II
leaks. Despite persistence, most patients with type III
endoleaks have had sac stabilization or regression during
follow-up (Fig 2, C ). The one patient who developed a
late type III endoleak has had sac expansion since this
Table I. Patient characteristics
Variable
Endoleak
(n  20)
No endoleak
(n  49)
P
value
Age (y)
Mean 72.2  13.2 73.2  7.2 .671
Range 35-85 57-86
Male sex (%) 80 47 .016
Hypertension (%) 75 90 .140
Diabetes (%) 15 20 .742
Renal insufficiency (%) 20 31 .554
Coronary artery disease (%) 50 39 .430
Peripheral vascular disease
(%) 20 16 .734
Tobacco use (%) 80 90 .431
Length of follow-up (mo) 21.6  15.3 15.6  14.2 .125
Table II. Aneurysm characteristics
Variable
Endoleak
(n  20)
No endoleak
(n  49) P value
Preoperative sac
diameter (mm)
Mean 69.4  10.5 60.6  11.0 .003
Range 54-102 40-100
No. stents 3.7  1.3 2.2  1.0 .0001
Saccular morphology
(%) 20 35 .265
Device type (% Talent) 75 53 .111
Sac diameter change
(mm) 0.13  7.2 2.89  9.1 .232
Length of stent
coverage (mm) 254.3  61.0 192.9  58.8 .0004
Table III. Effect of endoleak type on change in
aneurysm sac diameter
Endoleak type Sac diameter change (mm)
P
value*
Type I† (n  8) 2.9  8.5 .998
Type II‡ (n  7) 2.6  7.3 .136
Type III (n  4) 0.78  3.1 .649
*Compared with the no-endoleak group (2.89  9.1 mm).
†Compared with type II (P  .209) and type III (P  .648).
‡Compared with type III (P  .413).leak appeared.DISCUSSION
Although a great deal has been written about endoleaks
after EVAR, less is known about endoleaks after TEVAR.10-14
Earlier series involving stent graft repair of TAAs have shown
that endoleaks occur in 5% to 20% of patients, which is
similar to the endoleak incidence after EVAR.3-10 Manage-
ment has generally consisted of aggressive endovascular
repair of type I and type III endoleaks, with observation of
type II endoleaks.3-10
Endoleaks after TEVAR were not uncommon in our
series, occurring in 29% of patients. Although there have been
some data to suggest factors that may be predictive of sac
expansion after EVAR, little has been published regarding the
factors that are predictive of the development of endoleaks,
especially in patients after TEVAR.15,16 Consistent with these
studies, the presence of an endoleak led to significantly less sac
regression (0.13 7.2mm vs2.89 9.1mm; P .232;
Table II). Patients without endoleaks continued to have sac
regression during follow-up (Fig 3), although this was less
consistent with patients who developed endoleaks (Fig 2).
In this study, several differences between the group of
patients who developed endoleaks and those who did not
deserve further discussion. Although patients with and
without endoleaks were similar with respect to age distri-
bution and the prevalence of medical comorbidities, there
was a significantly larger proportion of male patients in the
endoleak group (80% vs 47%; P  .016; Table I). Further-
more, patients who developed endoleaks had more exten-
sive aneurysms at the time of repair. Preoperative sac diam-
eter was significantly larger in endoleak patients (69.4 
10.5 mm vs 60.6  11.0 mm; P  .003; Table II).
Additionally, significantly more stents (3.7  1.3 vs 2.2 
1.0; P  .0001) and a greater length of stent coverage
(254.3 61.0 mm vs 192.9 58.8 mm; P .0004) were
required to treat patients in the endoleak group.
These data suggest that patients requiring extensive
aortic coverage with multiple stents are at increased risk for
endoleak and perhaps may not do as well in the long term as
a result. In fact, there was a larger proportion of patients
with saccular morphology in the group without endoleaks
(35% vs 20%), although this failed to reach statistical signif-
icance (P  .265; Table II). Data also suggest that using
Table IV. Secondary procedures for treatment
of endoleaks*
Leak location Treatment Outcome
Distal Extension Resolved
Proximal Extension Resolved
Proximal Extension Resolved
Distal Extension Resolved
Proximal and distal Extension Proximal resolved,
distal persists
Distal type I, type II,
type III
Junctional stent Resolution of type
III
*All endoleaks are type I except where indicated.devices that are longer instead of multiple short devices may
One patient developed a late endoleak at 2 years (‡).
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postoperative endoleak. This is illustrated by the larger
proportion of Talent stents used in patients who developed
endoleaks vs those who did not (75% vs 53%), although this
also failed to reach statistical significance (P  .111). The
Talent stent has shorter lengths than the TAG device and
necessitates multiple stents more often. With the newer
Talent devices, which are longer, it is anticipated that this
will not be as much of an issue.
Similar to the approach taken after EVAR, type I en-
doleaks were treated by using endovascular techniques. These
techniques were successful in four of eight patients (Table IV).
After attempted endovascular repair, one of the eight type I
endoleak patients continued to demonstrate an endoleak. The
contribution of type I endoleaks on failure of sac regression is
well illustrated in Fig 2, A; satisfactory repair of type I en-
doleaks results in dramatic sac regression for most patients.
This is likely responsible for the overall decrease in sac diame-
ter (0.78  3.1 mm) in this patient population (Table III).
The virulence of type I endoleaks was demonstrated by one of
our patients who experienced fatal rupture of his aneurysm
after an unsuccessful attempt at endoleak remediation. This
patient represents the only aneurysm-related death in the
cohort but was not included in the overall analysis because he
had follow-up less than 1 month.
Despite overall aneurysmenlargement (2.67.3mm), as
with other series, type II endoleaks were not actively treated.
In addition, 29% (2/7) of them spontaneously thrombosed.
After thrombosis, these aneurysms continued to grow, one by
17 mm at last follow-up (Fig 2, B). In this patient, despite no
further evidence of endoleak, the sac continues to expand and
is largely responsible for the overall increase in aneurysm size
for the type II endoleak group.Treatment of type II endoleaks
via transarterial or translumbar embolization can be consider-
ably more difficult than treatment of type II endoleaks after
AAA repair. This is because collateral circulation in the tho-
racic aorta is not developed as well as in the abdominal aorta.
In addition, accessing the endoleak sac in TAA patients by
Fig 3. Bar graph depicting the average change in aneurysm sac
diameter in patients with no endoleak. The number of patients at
each time period is indicated in parentheses.Fig 2. A, Graphic plot of change in aneurysm sac diameter over
time after endovascular repair of thoracic aortic aneurysms
(TEVAR) in patients with postoperative type I endoleaks. Solid
lines represent patients who successfully underwent endovascular
treatment at the time indicated (*). The patient who had unsuc-
cessful endovascular treatment (dotted line) was also treated at the
time marked (*). Spontaneous endoleak thrombosis occurred in
three patients (dashed line) at the times indicated (x). B, Plot of
change in aneurysm sac diameter over time after TEVAR in pa-
tients with type II endoleaks. Two patients had spontaneous
thrombosis of the endoleak (dashed line) at the times indicated (x).
C, Plot of change in aneurysm sac diameter over time after TEVAR
in patients with type III endoleaks. All leaks remained persistent.using a direct puncture often involves traversing lung, which
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embolization of endoleaks in AAA patients.17 Despite these
risks, with continued sac expansion it is uncertain whether the
watchful waiting approach to type II endoleaks that has been
advocated is warranted in TAA patients.
Type III endoleaks were the least common and could
occur late. One patient was treated with a junctional stent,
with resolution (Table IV). Although most type III en-
doleaks remained persistent, these patients continued to
have sac regression over time (Fig 2, C).
Limitations to this study exist. The absolute numbers in
each category were low, thus contributing to type II error
and failure to recognize significant contributors to en-
doleak formation and sac expansion. CTA was used to
diagnose and to classify the endoleaks in this series. On the
basis of findings of endoleaks after AAA, CTA classification
of endoleaks is less accurate than classification with diag-
nostic angiography. Furthermore, magnetic resonance an-
giography or intravascular ultrasonography may also pro-
vide insight into the classification of endoleaks and might
be considered. Some of the patients classified as having type
II endoleaks on CTA could have small type I or type III
endoleaks. Because the aneurysms are continuing to grow,
these other modalities may shed some light on this possi-
bility and allow for further treatment.
In conclusion, this series demonstrates that endoleaks
occur after TEVARwith an incidence similar to that seen after
EVAR. The presence of an endoleak is associated with less sac
regression. Patients with larger, more extensive aneurysms are
at increased risk for the development of endoleaks. Type I
endoleaks are often amenable to repair using endovascular
techniques, with subsequent sac regression. Patients with type
II endoleaks tend to continue to have sac expansion, and
consideration should be given to further evaluating the nature
of the endoleak to determine whether it is amenable to treat-
ment. Regardless, all patients after TEVAR should be fol-
lowed up closely and consistently to identify endoleaks so that
treatment, when indicated, can be offered to allow for optimal
outcomes in these patients.
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